Clinical effects of DHA supplementation in pediatric patients with cystic fibrosis

Minerva Pediatrica

Volumn 65, Issue 4, 2013, Pages 389-398

  Leggieri, E ^a   De Biase, R V ^a   Savi, D ^a   Zullo, S ^a   Halili, I ^a   Quattrucci, S ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cystic fibrosis; Dietary supplements; Fatty acid; Inflammation

Indexed keywords

CALGRANULIN; DOCOSAHEXAENOIC ACID; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CYSTIC FIBROSIS; DIET SUPPLEMENTATION; DRUG SAFETY; DRUG TOLERABILITY; DYNAMOMETRY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; MALE; NUTRITIONAL PARAMETERS; PRESCHOOL CHILD; RESPIRATORY FUNCTION; SCHOOL CHILD; DIET THERAPY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; CHILD; CYSTIC FIBROSIS; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; FEMALE; HUMANS; MALE;

EID: 84884966507     PISSN: 00264946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Hyde SC, Emsley P, Hartshorn MJ, Mimmack MM, Gileadi U, Pearce SR et al. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 1990;346:362-5.
2. Welsh MJ, Smith AE. Cystic fibrosis. Sci Am 1995;273:52-9.
3. Mastella G. Fibrosi cistica. Milan: Edizioni CE.D.RI.M; 1998.
4. Alicandro G, Faelli N, Gagliardini R, Santini B, Magazzù G, Biffi A et al. A randomized placebo-controlled study on higt-dose oral algal docosahexaenoic acid supplementation in chindren with cystic fibrosis. Prostaglandins Leukot Essent Fatty Acids 2013;88:163-9.
5. Colombo C, Bennato V, Costantini D, Valmarana L, Daccò V, Zazzeron L et al. Dietary and circulating polyunsaturated fatty acids in cystic fibrosis: are they related to clinical outcomes? J Pediatr Gastroenterol Nutr 2006;43:660-5. (Pubitemid 44863695)
6. Risé P, Volpi S, Colombo C, Padoan RF, D'Orazio C, Ghezzi S et al. Whole blood fatty acid analysis with micromethod in cystic fibrosis and pulmonary disease. J Cyst Fibros 2010;9:228-33.
7. Roulet M, Frascarolo P, Rappaz I, Pilet M. Essential fatty acid deficiency in well nourished young cystic fibrosis patients. Eur J Pediatr 1997;156.952-6.
8. Freedman SD, Blanco PG, Zaman MM, Shea JC, Ollero M, Hopper IK et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 2004;350:560-9. (Pubitemid 38160786)
9. Keen C, Olin AC, Eriksson S, Ekman A, Lindblad A, Basu S et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2010;50:537-44.
10. Serhan CN. Resolution phase of inflammation: novel endogenous anti- inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 2007;25:101-37. (Pubitemid 46697904)
11. Freedman SD, Katz MH, Parker EM, Laposata M, Urman MY, Alvarez JG. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in CFTR-/-mice. Proc Natd Aceed Sci 1999;96:13995-4000.
12. Beharry S, Ackerley C, Corey M, Kent G, Heng YM, Christensen H et al. Long-term docosahexaenoic acid therapy in a congenic murine model of cystic fibrosis. AJP Gastrointest Liver Physiol 2007;292:G839-G848. (Pubitemid 46440393)
13. Olveira G, Olveira C, Acosta E, Espíldora F, Garrido- Sánchez L, García-Escobar E et al. Fatty acid supplements improve respiratory, inflammatory and nutritional parameters in adults with cystic fibrosis. Arch Bronconeumol 2010;46:70-7.
14. Lepage G, Yesair DW, Ronco N, Champagne J, Bureau N, Chemtob S et al. Effect of an organized lipid matrix on lipid absorption and clinical outcomes in patients with cystic fibrosis. J Pediatr 2002;141:178-85.
15. Van Biervliet S, Devos M, Delhaye T, Van Biervliet JP, Robberecht E, Christophe A. Oral DHA supplementation in DeltaF508 homozygous cystic fibrosis patients. Prostaglandins Leukot Essent Fatty Acids 2008;78:109-15. (Pubitemid 351318229)
16. Christophe A, Robberecht E, Franckx H, De Baets F, van de Pas M. Effect of administration of gamma-linolenic acid on the fatty acid composition of serum phospholipids and cholesteryl esters in patients with cystic fibrosis. Ann Nutr Metab 1994;38:40-7. (Pubitemid 24065486)
17. Christophe A, Robberecht E, De Baets F, Franckx H. Increase of long chain omega-3 fatty acids in the major serum lipid classes of patients with cystic fibrosis. Ann Nutr Metab 1992;36:304-12. (Pubitemid 23028444)
18. De Vizia B, Raia V, Spano C, Pavlidis C, Coruzzo A, Alessio M. Effect of an 8-month treatment with omega-3 fatty acids (eicosapentaenoic and docosahexaenoic) in patients with cystic fibrosis. J Parenter Enteral Nutr 2003;27:52-7. (Pubitemid 36105644)
19. Katz DP, Manner T, Furst P, Askanazi J. The use of an intravenous fish oil emulsion enriched with omega-3 fatty acids in patients with cystic fibrosis. Nutrition 1996;12:334-9. (Pubitemid 26294994)
20. Henderson WR, Astley SJ, McCready MM, Kushmerick P, Casey S, Becker JW et al. Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insuficiency and in healthy control subjects. J Pediatr 1994;124:400-8. (Pubitemid 24094450)
21. Lawrence RH, Sorrell TC. Eicosapentaenoic acid modulates neutrophil leukotriene B4 receptor expression in cystic fibrosis. Clin Exp Immunol 1994;98:12-6. (Pubitemid 24315444)
22. Kurlandsky LE, Bennink MR, Webb PM, Ulrich PJ, Baer LJ. The absorption and effect of dietary supplementation with omega-3 fatty acids on serum leukotriene B4 in patients with cystic fibrosis. Pediatr Pulmonol 1994;18:211-7. (Pubitemid 2161378)
23. Thies NH. The effect of 12 months' treatment with eicosapentaenoic acid in five children with cystic fibrosis. J Paediatr Child Health 1997;33:349-51. (Pubitemid 27396193)
24. Lloyd-Still JD; Powers CA, Hoffman DR, Boyd-Trull K, Lester LA, Benisek DC et al. Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study. Nutrition 2006;22:36-46. (Pubitemid 43175783)
25. Jumpsen JA, Brown NE, Thomson AB, Paul Man SF, Goh YK, Ma D et al. Fatty acids in blood and intestine following docosahexaenoic acid supplementation in adults with cystic fibrosis. J Cyst Fibros 2006;5:77-84
26. Panchaud A, Sauty A, Kernen Y, Decosterd LA, Buclin T, Boulat O et al. Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomized, crossover placebo controlled trial. Clin Nutr. 2006;25:418-27. (Pubitemid 43843016)
27. Durieu I, Vericel E, Guichardant D, Roth H, Steghens JP, Drai J et al. Fatty acids platelets and oxidative markers following intravenous n-3 fatty acids administration in cystic fibrosis: An open pilot observational study. J Cyst Fibros 2007;6:320-6. (Pubitemid 47324149)
28. Oliver C, Jahnke N. Omega-3 fatty acids for cystic fibrosis. Cochrane Database Syst Rev 2011;CD002201.
29. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis1983;127:725-34.
30. WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards: Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age:methods and development. Geneva: World Health Organization; 2006.
31. Van Biervliet S, Van Biervliet JP, Robberecht E, Christophe A. Docosahexaenoic acid trials in cystic fibrosis: a review of the rationale behind the clinical trials. J Cyst Fibrosis 2005;4:27-34. (Pubitemid 40347774)
32. Christophe A, Robberecht E. Directed modification instead of normalization of fatty acid patterns in cystic fibrosis an emerging concept. Curr Opin Clin Nutr Metab Care 2001;4:111-3. (Pubitemid 34755452)
33. McNutt NS. The S100 family of multipurpose calcium-binding proteins. J Cutan Pathol 1998;25:521-9. (Pubitemid 28552506)
34. Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007;81:28-37. (Pubitemid 46021248)
35. Foell D, Wittkowski H, Roth J. Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut 2009,58:859-68.
36. Döring G, Elborn JS, Johannesson M, de Jonge H, Griese M, Smyth A et al. Clinical trials in cystic fibrosis. J Cyst Fibrosis 2007;6:85-99. (Pubitemid 46388947)